UCB’s Post

Understanding the long-term effects of medications is essential for ensuring patient safety and optimizing healthcare outcomes. However, comprehensive longitudinal data to study effects of drugs over extended periods can be hard to come by. This new whitepaper follows an insightful panel discussion at the DIA Global Annual Meeting, and addresses some of challenges posed by a lack of broad and complete longitudinal data and challenges that could arise in the conduct of long-term safety studies. The authors describe a hypothetical study design to overcome some of these challenges and explore other ways researchers may overcome obstacles. Authors: Naomi Boxall, Ron Herings (PHARMO Institute, part of Lumanity), Nikita Jeswani, Steven Weisman PhD (Lumanity), Vera Ehrenstein (Aarhus University). Read the whitepaper: https://buff.ly/3yeX6lm #DrugSafety #DIA2024 #RWE #RealWorldEvidence #RWD #LongTermSafety #LongitudinalData #StudyDesign #PatientSafety #OutcomesResearch

In recent years, NICE - National Institute for Health and Care Excellence has introduced a new way of deciding how much value to assign to some treatments, which is called the severity modifier. In our latest blog, ABPI Head of HTA and Market Access, Orban Holdgate discusses the severity modifier, and why is it important for understanding medicines access for patients. Read here: https://lnkd.in/epEsWpab

Earlier today, we introduced a new behavioral tool initiative in partnership with Observia. The World Health Organization, in its 2003 report on medication adherence, states that “increasing the effectiveness of adherence interventions may have a far greater impact on the health of the population than any improvement in specific medical treatment.” The new #MMAS+#SPUR tool benefits from experience and simplicity with the MMAS, and a way to examine a patients risk of non-adherence through the SPUR model. Researchers and healthcare professionals worldwide will soon have access to a new tool set to revolutionize patient adherence outcomes. Observia the company called adherence. 1. Sabaté E. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.

Unmet needs and cost drivers such as large populations, total cost of care, the influx of new patients, and required life-long treatments are crucial to payer management in critical therapeutic areas. In the International Journal of Science and Research (IJSR), MMIT’s Dinesh Kabaleeswaran and Julie Mohammed share research results across 123 payers. https://ow.ly/JOnS50Sa7VC #Healthcare #Biosimilars #PayerManagement

With responses from 123 Payers this article underscores the strategic decisions of payers in cost management and anticipate future trends in payer strategies, including value-based contracting and biosimilar utilization.

𝐖𝐚𝐧𝐭 𝐭𝐨 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭𝐢𝐚𝐭𝐞 𝐲𝐨𝐮𝐫 𝐩𝐫𝐚𝐜𝐭𝐢𝐜𝐞 𝐢𝐧 𝐚 𝐜𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐚𝐧𝐝 𝐢𝐦𝐩𝐫𝐨𝐯𝐞 𝐬𝐚𝐭𝐢𝐬𝐟𝐚𝐜𝐭𝐢𝐨𝐧? Focus on learning more about integrative and functional medicine, to get to the root causes of illness, and blend traditional medical practices with evidence-based alternative therapies. By incorporating these approaches, you can: • Enhance outcomes • Address chronic conditions more effectively • Meet the growing patient demand for holistic health solutions Become part of a program that is changing healthcare: https://lnkd.in/eM9aX8GU

𝐖𝐚𝐧𝐭 𝐭𝐨 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭𝐢𝐚𝐭𝐞 𝐲𝐨𝐮𝐫 𝐩𝐫𝐚𝐜𝐭𝐢𝐜𝐞 𝐢𝐧 𝐚 𝐜𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐚𝐧𝐝 𝐢𝐦𝐩𝐫𝐨𝐯𝐞 𝐬𝐚𝐭𝐢𝐬𝐟𝐚𝐜𝐭𝐢𝐨𝐧? Focus on learning more about integrative and functional medicine, to get to the root causes of illness, and blend traditional medical practices with evidence-based alternative therapies. By incorporating these approaches, you can: • Enhance outcomes • Address chronic conditions more effectively • Meet the growing patient demand for holistic health solutions Become part of a program that is changing healthcare: https://lnkd.in/ebYfPwNV

Discover a Wealth of Knowledge with Our Latest Reports!! 📚 Dive into the fascinating world of point-of-care diagnostics, a market that reached an impressive $36.9 billion in 2023. These innovative solutions bring medical testing right to the patient's side, speeding up crucial decisions and treatments. Essential for enhancing healthcare accessibility, they are especially valuable in remote locations and emergency situations.. The market is set to soar, growing from $40.6 billion in 2024 to an impressive $65.9 billion by 2029, boasting a healthy compound annual growth rate (CAGR) of 10.2%. Fueling this remarkable expansion are breakthroughs in diagnostic technologies, a surging interest in at-home healthcare solutions, and the increasing prevalence of chronic diseases.. Stay ahead of the curve with our latest market report and explore the future of diagnostics technology! 🩺 https://bit.ly/3zN8Kod #HealthcareInnovation #PointOfCare #MedicalDevices #Diagnostics #MarketTrends #GlobalHealthcare #CAGR #TechInHealth #HealthcareTransformation #MedicalTechnology

Let's talk about an essential term in healthcare: 'screening.' Screening involves tests and exams that detect diseases or conditions early, even before symptoms arise, allowing for timely and effective intervention. From routine blood tests to advanced cancer screenings, these procedures are vital in catching health issues early. We are dedicated to helping patients from all linguistic backgrounds comprehend their screening procedures and results. Clear communication ensures that everyone can make informed decisions about their health.

Understanding the long-term effects of medications is crucial for patient safety and improving healthcare outcomes. However, obtaining comprehensive longitudinal data to study drug effects over extended periods can be challenging. Lumanity’s new white paper, following an insightful panel discussion at the DIA Global Annual Meeting, delves into these challenges. It addresses the difficulties posed by the lack of extensive and complete longitudinal data and the potential hurdles in conducting long-term safety studies. The authors propose a hypothetical study design to navigate some of these challenges and explore additional solutions for researchers.   Authors include Naomi Boxall, Ron Herings, Nikita Jeswani, Steven Weisman, and Vera Ehrenstein. Read the paper at https://buff.ly/4c9z7lb   #RWE #RealWorldEvidence #RWD #LongTermSafety #LongitudinalData #PatientSafety #OutcomesResearch #DrugSafety #DIA2024